1. Home
  2. NKTX vs EOLS Comparison

NKTX vs EOLS Comparison

Compare NKTX & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.93

Market Cap

247.4M

Sector

Health Care

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$5.30

Market Cap

284.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTX
EOLS
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.4M
284.3M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
NKTX
EOLS
Price
$2.93
$5.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$11.33
$15.50
AVG Volume (30 Days)
960.2K
668.9K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
11.88
1.23
EPS
N/A
N/A
Revenue
N/A
$297,176,000.00
Revenue This Year
N/A
$13.27
Revenue Next Year
N/A
$17.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.61
52 Week Low
$1.63
$3.86
52 Week High
$3.65
$12.24

Technical Indicators

Market Signals
Indicator
NKTX
EOLS
Relative Strength Index (RSI) 58.40 63.37
Support Level $1.88 $4.02
Resistance Level $3.65 $5.52
Average True Range (ATR) 0.28 0.25
MACD -0.02 0.07
Stochastic Oscillator 49.64 84.17

Price Performance

Historical Comparison
NKTX
EOLS

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: